Drug intelligence / Profile preview

SNC112

Development stage: Preclinical
Lead developer: Simnova Biotherapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SNC112 is a preclinical, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Shanghai Simnova Biotechnology. It is designed to target both B-cell maturation antigen (BCMA) and G-protein coupled receptor family C group 5 member D (GPRC5D), which are highly expressed on multiple myeloma cells. The mechanism of action involves the inhibition of both BCMA and GPRC5D, aiming to enhance anti-tumor activity against multiple myeloma. This approach leverages the cytotoxic potential of NK cells engineered with CARs specific for these two antigens[1][2][4].

Other names: BCMA/GPRC5D dual targeting CAR-NK

Targets

GPRC5DBCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on SNC112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNC112.

Explore the full profile